ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet13002ometendo-13026Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL PRACTICE GUIDELINESКлинические рекомендации «Гиперпролактинемия» (проект)Clinical guidelines ‘Hyperprolactinemia’ (draft)https://orcid.org/0000-0002-8175-7886ДедовИ. И.DedovI. I.

Дедов И.И., д.м.н., профессор, академик РАН 

Москва

Ivan I. Dedov, MD, PhD, Professor

Moscow

dedov@endocrincentr.ruhttps://orcid.org/0000-0002-5634-7877МельниченкоГ. А.MelnichenkoG. A.

Мельниченко Г.А., д.м.н., профессор 

Москва

Galina A. Melnichenko, MD, PhD, Professor

Moscow

teofrast2000@mail.ruhttps://orcid.org/0000-0002-0327-4619ДзерановаЛ. К.DzeranovaL. K.

Дзеранова Л.К., д.м.н. 

117292, г. Москва, ул. Дм. Ульянова, д. 11

Larisa K. Dzeranova, MD, PhD

11 Dm. Ulyanova street, 117036 Moscow

dzeranovalk@yandex.ruhttps://orcid.org/0000-0001-8425-0020АндрееваЕ. Н.AndreevaE. N.

Андреева Е.Н., д.м.н. 

Москва

Elena N. Andreeva, MD, PhD

Moscow

endogin@mail.ruhttps://orcid.org/0000-0003-0042-7680ГриневаЕ. Н.GrinevaE. N.

Гринева Е.Н., д.м.н., профессор 

Санкт-Петербург

AuthorID: 303850

Elena N. Grineva, MD, PhD

Saint-Petersburg

grineva_e@mail.ruhttps://orcid.org/0000-0002-5130-4157МароваЕ. И.MarovaE. I.

Марова Е.И., д.м.н., проф. 

Москва

AuthorID: 105168

Evgenia I. Marova, MD, PhD, professor

Moscow

marova-e@mail.ruhttps://orcid.org/0000-0002-9717-9742МокрышеваН. Г.MokryshevaN. G.

Мокрышева Н.Г., д.м.н., профессор 

Москва

Natalia G. Mokrysheva

Moscow

nm70@mail.ruhttps://orcid.org/0000-0001-6539-466XПигароваЕ. А.PigarovaE. A.

Пигарова Е.А., д.м.н. 

Москва

Ekaterina A. Pigarova, MD, PhD

Moscow

kpigarova@gmail.comhttps://orcid.org/0000-0001-7470-1676ВоротниковаС. Ю.VorotnikovaS. Y.

Воротникова С.Ю., к.м.н. 

Москва

Svetlana Y. Vorotnikova, MD, PhD

Moscow

bra_svetix@list.ruhttps://orcid.org/0000-0002-9816-5043ФедороваН. С.FedorovaN. S. 

Федорова Н.С., к.м.н. 

Москва

Natalya S. Fedorova, MD, PhD

Moscow

fedorova.n.s.12@gmail.comhttps://orcid.org/0000-0003-0047-7223ШутоваА. С.ShutovaA. S.

Шутова А.С. 

Москва

Aleksandra S. Shutova, MD

Moscow

shutova.aleksandra@gmail.comhttps://orcid.org/0000-0001-9119-2447ПржиялковскаяЕ. Г.PrzhiyalkovskayaE. G.

Пржиялковская Е.Г., к.м.н. 

Москва

Elena G. Przhiyalkovskaya, MD, PhD

Moscow

przhiyalkovskaya.elena@gmail.comhttps://orcid.org/0000-0003-3261-7366ИловайскаяИ. А.IlovaуskayaI.  A. 

Иловайская И.А., д.м.н. 

Москва

Researcher ID: I-1159-2014

Irena A. Ilovaуskaya, РhD

Moscow

https://orcid.org/0000-0003-3870-6394РоманцоваТ. И.RomantsovaT. I.

Романцова Т.И., д.м.н., профессор 

Москва

Tatiana I. Romantsova, MD, PhD, Professor

Moscow

romantsovatatiana@rambler.ruhttps://orcid.org/0000-0002-1709-466XДогадинС. А.DogadinS. A.

Догадин С.А., д.м.н., профессор 

Красноярск

Researcher ID: P-4467-2015;

Scopus Author ID: 6506273878

Sergey A. Dogadin, MD, PhD, Professor

Krasnoyarsk

sadogadin@gmail.comhttps://orcid.org/0000-0001-9253-8075СуплотоваЛ. А.SuplotovaL. A.

Суплотова Л.А., д.м.н., профессор 

Тюмень

Liudmila A. Suplotova, MD, PhD, Professor

Tyumen

suplotovala@mail.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationСеверо-Западный федеральный медицинский исследовательский центр им. В.А. АлмазоваРоссияAlmazov National Medical Research CentreRussian FederationМосковский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияMoscow Regional Research and Clinical InstituteRussian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)РоссияI.M.Sechenov First Moscow State Medical UniversityRussian FederationКрасноярский государственный медицинский университет им. В.Ф. Войно-Ясенецкого; КГБУЗ «Краевая клиническая больница» Минздрава Красноярского краяРоссияKrasnoyarsk State Medical University; Regional Clinical HospitalRussian FederationТюменский государственный медицинский университетРоссияTyumen State Medical UniversityRussian Federation202326072023202170188Copyright © Дедов И.И., Мельниченко Г.А., Дзеранова Л.К., Андреева Е.Н., Гринева Е.Н., Марова Е.И., Мокрышева Н.Г., Пигарова Е.А., Воротникова С.Ю., Федорова Н.С., Шутова А.С., Пржиялковская Е.Г., Иловайская И.А., Романцова Т.И., Догадин С.А., Суплотова Л.А., 20232023Дедов И.И., Мельниченко Г.А., Дзеранова Л.К., Андреева Е.Н., Гринева Е.Н., Марова Е.И., Мокрышева Н.Г., Пигарова Е.А., Воротникова С.Ю., Федорова Н.С., Шутова А.С., Пржиялковская Е.Г., Иловайская И.А., Романцова Т.И., Догадин С.А., Суплотова Л.А.Dedov I.I., Melnichenko G.A., Dzeranova L.K., Andreeva E.N., Grineva E.N., Marova E.I., Mokrysheva N.G., Pigarova E.A., Vorotnikova S.Y., Fedorova N.S., Shutova A.S., Przhiyalkovskaya E.G., Ilovaуskaya I.A., Romantsova T.I., Dogadin S.A., Suplotova L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/13026

Гиперпролактинемия — стойкое избыточное содержание пролактина в сыворотке крови. Синдром гиперпролактинемии — это симптомокомплекс, возникающий на фоне гиперпролактинемии, наиболее характерным проявлением которого является нарушение функции репродуктивной системы. Причиной гиперпролактинемии могут быть разнообразные состояния эндогенного и экзогенного характера. Основной метод лечения гиперпролактинемии — терапия агонистами дофамина, при опухолевом генезе также применяются хирургический и лучевой методы. Около 15% пациентов резистентны к терапии агонистами дофамина, что обусловливает необходимость формирования индивидуальной тактики ведения данной категории больных. Для предотвращения патологических изменений, обусловленных гиперпролактинемией, крайне важными являются своевременная диагностика и определение оптимальной схемы лечения. В статье представлен проект клинических рекомендаций по гиперпролактинемии, в котором приведен современный алгоритм обследования, рассмотрены основные принципы лабораторной, инструментальной диагностики и подходы к лечению.

Hyperprolactinemia is a persistent excess of the blood serum prolactin. The syndrome contains various symptoms, the most characteristic is a violation of the reproductive system. There are multiple endogenous and exogenous causes of hyperprolactinemia. The main treatment method is dopamine agonist therapy, in case of prolactinoma existence, surgical and radiation methods can be applied. About 15% of patients are resistant to dopamine agonist therapy, which determines creation of individual management tactics. The article presents a draft of clinical guidelines for the diagnosis and treatment of hyperprolactinemia, which provides a modern examination algorithm, discusses the basic principles of diagnostics and treatment approaches.

гиперпролактинемияаденома гипофизапролактиномаагонисты дофаминарезистентность к терапииhyperprolactinemiapituitary adenomaprolactinomadopamine agonistsresistance to therapyReferencesWang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: A systematic review and meta-analysis. Syst Rev. 2006;1(1):1-12. doi: https://doi.org/10.1186/2046-4053-1-33Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: A systematic review and meta-analysis. Syst Rev. 2006;1(1):1-12. doi: https://doi.org/10.1186/2046-4053-1-33Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: https://doi.org/10.1210/jc.2010-1692Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: https://doi.org/10.1210/jc.2010-1692Donadio F, Barbieri A, Angioni R, et al. Patients with macroprolactinaemia: Clinical and radiological features. Eur J Clin Invest. 2007;37(7):552-557. doi: https://doi.org/10.1111/j.1365-2362.2007.01823.xDonadio F, Barbieri A, Angioni R, et al. Patients with macroprolactinaemia: Clinical and radiological features. Eur J Clin Invest. 2007;37(7):552-557. doi: https://doi.org/10.1111/j.1365-2362.2007.01823.xJoseph McKenna T. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf ). 2009;71(4):466-469. doi: https://doi.org/10.1111/j.1365-2265.2009.03577.xJoseph McKenna T. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf ). 2009;71(4):466-469. doi: https://doi.org/10.1111/j.1365-2265.2009.03577.xSchlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: A prospective analysis. Obstet Gynecol Surv. 1989;44(9):684-685. doi: https://doi.org/10.1097/00006254-198909000-00016Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: A prospective analysis. Obstet Gynecol Surv. 1989;44(9):684-685. doi: https://doi.org/10.1097/00006254-198909000-00016Buchfelder M, Schlaffer SM, Zhao Y. The optimal surgical techniques for pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101299. doi: https://doi.org/10.1016/j.beem.2019.101299Buchfelder M, Schlaffer SM, Zhao Y. The optimal surgical techniques for pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101299. doi: https://doi.org/10.1016/j.beem.2019.101299Jones PS, Swearingen B. Intraoperative MRI for pituitary adenomas. Neurosurg Clin N Am. 2019;30(4):413-420. doi: https://doi.org/10.1016/j.nec.2019.05.003Jones PS, Swearingen B. Intraoperative MRI for pituitary adenomas. Neurosurg Clin N Am. 2019;30(4):413-420. doi: https://doi.org/10.1016/j.nec.2019.05.003Bayrak A, Saadat P, Mor E, et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005;84(1):181-185. doi: https://doi.org/10.1016/j.fertnstert.2005.01.102Bayrak A, Saadat P, Mor E, et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005;84(1):181-185. doi: https://doi.org/10.1016/j.fertnstert.2005.01.102Kinoshita M, Tanaka H, Arita H, et al. Pituitary-targeted dynamic contrast-enhanced multisection CT for detecting MR imaging–occult functional pituitary microadenoma. Am J Neuroradiol. 2015;36(5):904-908. doi: https://doi.org/10.3174/ajnr.A4220Kinoshita M, Tanaka H, Arita H, et al. Pituitary-targeted dynamic contrast-enhanced multisection CT for detecting MR imaging–occult functional pituitary microadenoma. Am J Neuroradiol. 2015;36(5):904-908. doi: https://doi.org/10.3174/ajnr.A4220Tosaka M, Nagaki T, Honda F, et al. Multi-slice computed tomographyassisted endoscopic transsphenoidal surgery for pituitary macroadenoma: A comparison with conventional microscopic transsphenoidal surgery. Neurol Res. 2015;37(11):951-958. doi: https://doi.org/10.1179/1743132815Y.0000000078Tosaka M, Nagaki T, Honda F, et al. Multi-slice computed tomographyassisted endoscopic transsphenoidal surgery for pituitary macroadenoma: A comparison with conventional microscopic transsphenoidal surgery. Neurol Res. 2015;37(11):951-958. doi: https://doi.org/10.1179/1743132815Y.0000000078Buchfelder M, Schlaffer S. Imaging of pituitary pathology. American Journal of Neuroradiology. 2014;36:151-166. doi: https://doi.org/10.1016/B978-0-444-59602-4.00011-3Buchfelder M, Schlaffer S. Imaging of pituitary pathology. American Journal of Neuroradiology. 2014;36:151-166. doi: https://doi.org/10.1016/B978-0-444-59602-4.00011-3Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf ). 2006;65(2):265-273. doi: https://doi.org/10.1111/j.1365-2265.2006.02562.xCasanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf ). 2006;65(2):265-273. doi: https://doi.org/10.1111/j.1365-2265.2006.02562.xMolitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011;25(6):885-896. doi: https://doi.org/10.1016/j.beem.2011.05.011Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011;25(6):885-896. doi: https://doi.org/10.1016/j.beem.2011.05.011Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology. 2006;67(7):1225-1229. doi: https://doi.org/10.1212/01.wnl.0000238508.68593.1dYamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology. 2006;67(7):1225-1229. doi: https://doi.org/10.1212/01.wnl.0000238508.68593.1dGrigg J, Worsley R, Thew C, et al. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017;234(22):3279-3297. doi: https://doi.org/10.1007/s00213-017-4730-6Grigg J, Worsley R, Thew C, et al. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017;234(22):3279-3297. doi: https://doi.org/10.1007/s00213-017-4730-6Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14(4):228-238. doi: https://doi.org/10.2165/00002018-199614040-00003Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14(4):228-238. doi: https://doi.org/10.2165/00002018-199614040-00003Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-2522. doi: https://doi.org/10.1210/jcem.84.7.5810Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-2522. doi: https://doi.org/10.1210/jcem.84.7.5810Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159(4):11-14. doi: https://doi.org/10.1530/EJE-08-0365Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159(4):11-14. doi: https://doi.org/10.1530/EJE-08-0365Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12(3):153-157. doi: https://doi.org/10.1007/s11102-008-0134-2Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12(3):153-157. doi: https://doi.org/10.1007/s11102-008-0134-2Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009;70(1):104-108. doi: https://doi.org/10.1111/j.1365-2265.2008.03458.xHerring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009;70(1):104-108. doi: https://doi.org/10.1111/j.1365-2265.2008.03458.xDevin JK, Lakhani VT, Byrd BF, Blevins LS. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 2008;14(6):672-677. doi: https://doi.org/10.4158/EP.14.6.672Devin JK, Lakhani VT, Byrd BF, Blevins LS. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 2008;14(6):672-677. doi: https://doi.org/10.4158/EP.14.6.672Lafeber M, Stades AME, Valk GD, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010;162(4):667-675. doi: https://doi.org/10.1530/EJE-09-0989Lafeber M, Stades AME, Valk GD, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010;162(4):667-675. doi: https://doi.org/10.1530/EJE-09-0989Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010;73(3):369-374. doi: https://doi.org/10.1111/j.1365-2265.2010.03827.xTan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010;73(3):369-374. doi: https://doi.org/10.1111/j.1365-2265.2010.03827.xDrake WM, Stiles CE, Howlett TA, et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014;99(1):90-96. doi: https://doi.org/10.1210/jc.2013-2254Drake WM, Stiles CE, Howlett TA, et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014;99(1):90-96. doi: https://doi.org/10.1210/jc.2013-2254Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169(3):359-366. doi: https://doi.org/10.1530/EJE-13-0231Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169(3):359-366. doi: https://doi.org/10.1530/EJE-13-0231Salvatori R. Dopamine agonist withdrawal in hyperprolactinemia: when and how. Endocrine. 2018;59(1):4-6. doi: https://doi.org/10.1007/s12020-017-1469-0Salvatori R. Dopamine agonist withdrawal in hyperprolactinemia: when and how. Endocrine. 2018;59(1):4-6. doi: https://doi.org/10.1007/s12020-017-1469-0Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50-61. doi: https://doi.org/10.1007/s12020-017-1444-9Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50-61. doi: https://doi.org/10.1007/s12020-017-1444-9Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349(21):2023-2033. doi: https://doi.org/10.1056/NEJMoa022657Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349(21):2023-2033. doi: https://doi.org/10.1056/NEJMoa022657Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005;63(1):26-31. doi: https://doi.org/10.1111/j.1365-2265.2005.02293.xBiswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005;63(1):26-31. doi: https://doi.org/10.1111/j.1365-2265.2005.02293.xDekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: Systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43-51. doi: https://doi.org/10.1210/jc.2009-1238Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: Systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43-51. doi: https://doi.org/10.1210/jc.2009-1238Passos VQ, Souza JJS, Musolino NRC, Bronstein MD. Long-term follow-up of prolactinomas: Normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab. 2002;87(8):3578-3582. doi: https://doi.org/10.1210/jcem.87.8.8722Passos VQ, Souza JJS, Musolino NRC, Bronstein MD. Long-term follow-up of prolactinomas: Normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab. 2002;87(8):3578-3582. doi: https://doi.org/10.1210/jcem.87.8.8722Kwancharoen R, Auriemma RS, Yenokyan G, et al. Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary. 2014;17(5):451-456. doi: https://doi.org/10.1007/s11102-013-0525-xKwancharoen R, Auriemma RS, Yenokyan G, et al. Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary. 2014;17(5):451-456. doi: https://doi.org/10.1007/s11102-013-0525-xVilar L, Albuquerque JL, Gadelha PS, et al. Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: Is it worthwhile? Front Endocrinol (Lausanne). 2015;6(5):151-166. doi: https://doi.org/10.3389/fendo.2015.00011Vilar L, Albuquerque JL, Gadelha PS, et al. Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: Is it worthwhile? Front Endocrinol (Lausanne). 2015;6(5):151-166. doi: https://doi.org/10.3389/fendo.2015.00011Carroll RW, Christodoulou P, Baynes KCR, Kahn DA. Hyperprolactinemia in a patient with a pituitary adenoma receiving antipsychotic drug therapy. J Psychiatr Pract. 2012;18(2):126-129. doi: https://doi.org/10.1097/01.pra.0000413279.95843.b5Carroll RW, Christodoulou P, Baynes KCR, Kahn DA. Hyperprolactinemia in a patient with a pituitary adenoma receiving antipsychotic drug therapy. J Psychiatr Pract. 2012;18(2):126-129. doi: https://doi.org/10.1097/01.pra.0000413279.95843.b5Dogansen SC, Cikrikcili U, Oruk G, et al. Dopamine agonistinduced impulse control disorders in patients with prolactinoma: A cross-sectional multicenter study. J Clin Endocrinol Metab. 2019;104(7):2527-2534. doi: https://doi.org/10.1210/jc.2018-02202Dogansen SC, Cikrikcili U, Oruk G, et al. Dopamine agonistinduced impulse control disorders in patients with prolactinoma: A cross-sectional multicenter study. J Clin Endocrinol Metab. 2019;104(7):2527-2534. doi: https://doi.org/10.1210/jc.2018-02202Barake M, Evins AE, Stoeckel L, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: A pilot study. Pituitary. 2014;17(2):150-156. doi: https://doi.org/10.1007/s11102-013-0480-6Barake M, Evins AE, Stoeckel L, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: A pilot study. Pituitary. 2014;17(2):150-156. doi: https://doi.org/10.1007/s11102-013-0480-6Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 2008;22(S2):56-62. doi: https://doi.org/10.1177/0269881107088436Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 2008;22(S2):56-62. doi: https://doi.org/10.1177/0269881107088436David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-1096. doi: https://doi.org/10.1016/S0149-2918(00)80086-7David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-1096. doi: https://doi.org/10.1016/S0149-2918(00)80086-7Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-218. doi: https://doi.org/10.1007/s11102-008-0106-6Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-218. doi: https://doi.org/10.1007/s11102-008-0106-6Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: A clinical review. Psychosomatics. 2014;55(1):29-36. doi: https://doi.org/10.1016/j.psym.2013.08.008Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: A clinical review. Psychosomatics. 2014;55(1):29-36. doi: https://doi.org/10.1016/j.psym.2013.08.008Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995-2010. doi: https://doi.org/10.1210/jc.2005-2847Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995-2010. doi: https://doi.org/10.1210/jc.2005-2847Miyagawa Y, Tsujimura A, Matsumiya K, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: A 30-year retrospective study. J Urol. 2005;173(6):2072-2075. doi: https://doi.org/10.1097/01.ju.0000158133.09197.f4Miyagawa Y, Tsujimura A, Matsumiya K, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: A 30-year retrospective study. J Urol. 2005;173(6):2072-2075. doi: https://doi.org/10.1097/01.ju.0000158133.09197.f4Williams MH. Drugs five years later. Ann Intern Med. 1981;95(4):464. doi: https://doi.org/10.7326/0003-4819-95-4-464Williams MH. Drugs five years later. Ann Intern Med. 1981;95(4):464. doi: https://doi.org/10.7326/0003-4819-95-4-464Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril. 1987;48(1):67-71. doi: https://doi.org/10.1016/S0015-0282(16)59292-9Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril. 1987;48(1):67-71. doi: https://doi.org/10.1016/S0015-0282(16)59292-9Aden U, Jung-Hoffmann C, Kuhl H. A randomized crossover study on various hormonal parameters of two triphasic oral contraceptives. Contraception. 1998;58(2):75-81. doi: https://doi.org/10.1016/S0010-7824(98)00071-7Aden U, Jung-Hoffmann C, Kuhl H. A randomized crossover study on various hormonal parameters of two triphasic oral contraceptives. Contraception. 1998;58(2):75-81. doi: https://doi.org/10.1016/S0010-7824(98)00071-7Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris). 2007;68(2-3):106-112. doi: https://doi.org/10.1016/j.ando.2007.03.008Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris). 2007;68(2-3):106-112. doi: https://doi.org/10.1016/j.ando.2007.03.008Alvarez-Tutor E, Forga-Llenas L, Rodriguez-Erdozain R, et al. Persistent increase of PRL after oral contraceptive treatment. Alterations in dopaminergic regulation as possible etiology. Arch Gynecol Obstet. 1999;263(1-2):45-50. doi: https://doi.org/10.1007/s004040050261Alvarez-Tutor E, Forga-Llenas L, Rodriguez-Erdozain R, et al. Persistent increase of PRL after oral contraceptive treatment. Alterations in dopaminergic regulation as possible etiology. Arch Gynecol Obstet. 1999;263(1-2):45-50. doi: https://doi.org/10.1007/s004040050261Testa G, Vegetti W, Motta T, et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception. 1998;58(2):69-73. doi: https://doi.org/10.1016/S0010-7824(98)00069-9Testa G, Vegetti W, Motta T, et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception. 1998;58(2):69-73. doi: https://doi.org/10.1016/S0010-7824(98)00069-9Fraietta R, Zylberstejn DS, Esteves SC. Hypogonadotropic hypogonadism revisited. Clinics. 2013;68(S1):81-88. doi: https://doi.org/10.6061/clinics/2013(Sup01)09Fraietta R, Zylberstejn DS, Esteves SC. Hypogonadotropic hypogonadism revisited. Clinics. 2013;68(S1):81-88. doi: https://doi.org/10.6061/clinics/2013(Sup01)09Auriemma RS, Galdiero M, Vitale P, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66-81. doi: https://doi.org/10.1159/000371851Auriemma RS, Galdiero M, Vitale P, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66-81. doi: https://doi.org/10.1159/000371851Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. 2014;117(3):421-428. doi: https://doi.org/10.1007/s11060-013-1270-8Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. 2014;117(3):421-428. doi: https://doi.org/10.1007/s11060-013-1270-8Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003;6(1):19-27. doi: https://doi.org/10.1023/A:1026225625897Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003;6(1):19-27. doi: https://doi.org/10.1023/A:1026225625897Salti IS, Mufarrij IS, Opitz JM. Familial cushing disease. Am J Med Genet. 1981;8(1):91-94. doi: https://doi.org/10.1002/ajmg.1320080111Salti IS, Mufarrij IS, Opitz JM. Familial cushing disease. Am J Med Genet. 1981;8(1):91-94. doi: https://doi.org/10.1002/ajmg.1320080111Maiter D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019;109(1):42-50. doi: https://doi.org/10.1159/000495775Maiter D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019;109(1):42-50. doi: https://doi.org/10.1159/000495775Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82(3):876-883. doi: https://doi.org/10.1210/jcem.82.3.3822Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82(3):876-883. doi: https://doi.org/10.1210/jcem.82.3.3822Losa M, Mortini P, Barzaghi R, et al. Surgical treatment of prolactinsecreting pituitary adenomas: Early results and long-term outcome. J Clin Endocrinol Metab. 2002;87(7):3180-3186. doi: https://doi.org/10.1210/jcem.87.7.8645Losa M, Mortini P, Barzaghi R, et al. Surgical treatment of prolactinsecreting pituitary adenomas: Early results and long-term outcome. J Clin Endocrinol Metab. 2002;87(7):3180-3186. doi: https://doi.org/10.1210/jcem.87.7.8645Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: https://doi.org/10.1210/jc.2010-1692Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: https://doi.org/10.1210/jc.2010-1692Qu X, Wang M, Wang G, et al. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: A singlecenter experience with 87 consecutive cases. Eur J Endocrinol. 2011;164(4):499-504. doi: https://doi.org/10.1530/EJE-10-0961Qu X, Wang M, Wang G, et al. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: A singlecenter experience with 87 consecutive cases. Eur J Endocrinol. 2011;164(4):499-504. doi: https://doi.org/10.1530/EJE-10-0961Song Y-J, Chen M-T, Lian W, et al. Surgical treatment for male prolactinoma. Medicine (Baltimore). 2017;96(2):e5833. doi: https://doi.org/10.1097/MD.0000000000005833Song Y-J, Chen M-T, Lian W, et al. Surgical treatment for male prolactinoma. Medicine (Baltimore). 2017;96(2):e5833. doi: https://doi.org/10.1097/MD.0000000000005833Lim S, Shahinian H, Maya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518-520. doi: https://doi.org/10.1016/S1470-2045(06)70728-8Lim S, Shahinian H, Maya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518-520. doi: https://doi.org/10.1016/S1470-2045(06)70728-8McCormack AI, McDonald KL, Gill AJ, et al. Low O6- methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf ). 2009;71(2):226-233. doi: https://doi.org/10.1111/j.1365-2265.2008.03487.xMcCormack AI, McDonald KL, Gill AJ, et al. Low O6- methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf ). 2009;71(2):226-233. doi: https://doi.org/10.1111/j.1365-2265.2008.03487.xHagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161(4):631-637. doi: https://doi.org/10.1530/EJE-09-0389Hagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161(4):631-637. doi: https://doi.org/10.1530/EJE-09-0389Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007;38(1):185-189. doi: https://doi.org/10.1016/j.humpath.2006.07.014Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007;38(1):185-189. doi: https://doi.org/10.1016/j.humpath.2006.07.014Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: Correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95(11):280-290. doi: https://doi.org/10.1210/jc.2010-0441Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: Correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95(11):280-290. doi: https://doi.org/10.1210/jc.2010-0441Sheehan JP, Pouratian N, Steiner L, et al. Gamma knife surgery for pituitary adenomas: Factors related to radiological and endocrine outcomes: Clinical article. J Neurosurg. 2011;114(2):303-309. doi: https://doi.org/10.3171/2010.5.JNS091635Sheehan JP, Pouratian N, Steiner L, et al. Gamma knife surgery for pituitary adenomas: Factors related to radiological and endocrine outcomes: Clinical article. J Neurosurg. 2011;114(2):303-309. doi: https://doi.org/10.3171/2010.5.JNS091635Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity. Radiother Oncol. 2009;93(3):597-601. doi: https://doi.org/10.1016/j.radonc.2009.09.011Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity. Radiother Oncol. 2009;93(3):597-601. doi: https://doi.org/10.1016/j.radonc.2009.09.011Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys. 2006;64(2):425-434. doi: https://doi.org/10.1016/j.ijrobp.2005.07.978Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys. 2006;64(2):425-434. doi: https://doi.org/10.1016/j.ijrobp.2005.07.978Pouratian N, Sheehan J, Jagannathan J, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery. 2006;59(2):255-264. doi: https://doi.org/10.1227/01.NEU.0000223445.22938.BDPouratian N, Sheehan J, Jagannathan J, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery. 2006;59(2):255-264. doi: https://doi.org/10.1227/01.NEU.0000223445.22938.BDCastinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009;94(9):3400-3407. doi: https://doi.org/10.1210/jc.2008-2772Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009;94(9):3400-3407. doi: https://doi.org/10.1210/jc.2008-2772Ježková J, Hána V, Kršek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf ). 2009;70(5):732-741. doi: https://doi.org/10.1111/j.1365-2265.2008.03384.xJežková J, Hána V, Kršek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf ). 2009;70(5):732-741. doi: https://doi.org/10.1111/j.1365-2265.2008.03384.xTsang RW, Brierley JD, Panzarella T, et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol. 1996;41(1):45-53. doi: https://doi.org/10.1016/S0167-8140(96)91807-1Tsang RW, Brierley JD, Panzarella T, et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol. 1996;41(1):45-53. doi: https://doi.org/10.1016/S0167-8140(96)91807-1Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril. 1979;31(4):363-372. doi: https://doi.org/10.1016/s0015-0282(16)43929-4Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril. 1979;31(4):363-372. doi: https://doi.org/10.1016/s0015-0282(16)43929-4Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Obstet Gynecol Surv. 1995;50(3):199-201. doi: https://doi.org/10.1097/00006254-199503000-00020Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Obstet Gynecol Surv. 1995;50(3):199-201. doi: https://doi.org/10.1097/00006254-199503000-00020Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485-534. doi: https://doi.org/10.1210/er.2005-9998Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485-534. doi: https://doi.org/10.1210/er.2005-9998Pekić S, Medic Stojanoska M, Popovic V. Hyperprolactinemia/ prolactinomas in the postmenopausal period: Challenges in diagnosis and management. Neuroendocrinology. 2019;109(1):28-33. doi: https://doi.org/10.1159/000494725Pekić S, Medic Stojanoska M, Popovic V. Hyperprolactinemia/ prolactinomas in the postmenopausal period: Challenges in diagnosis and management. Neuroendocrinology. 2019;109(1):28-33. doi: https://doi.org/10.1159/000494725Santharam S, Fountas A, Tampourlou M, et al. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf ). 2018;89(3):346-353. doi: https://doi.org/10.1111/cen.13765Santharam S, Fountas A, Tampourlou M, et al. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf ). 2018;89(3):346-353. doi: https://doi.org/10.1111/cen.13765Colao A, Abs R, Bárcena DG, et al. Pregnancy outcomes following cabergoline treatment: Extended results from a 12-year observational study. Clin Endocrinol (Oxf ). 2008;68(1):66-71. doi: https://doi.org/10.1111/j.1365-2265.2007.03000.xColao A, Abs R, Bárcena DG, et al. Pregnancy outcomes following cabergoline treatment: Extended results from a 12-year observational study. Clin Endocrinol (Oxf ). 2008;68(1):66-71. doi: https://doi.org/10.1111/j.1365-2265.2007.03000.xRobert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996;10(4):333-337. doi: https://doi.org/10.1016/0890-6238(96)00063-9Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996;10(4):333-337. doi: https://doi.org/10.1016/0890-6238(96)00063-9Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. 2020;23(1):65-69. doi: https://doi.org/10.1007/s11102-019-01010-5Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. 2020;23(1):65-69. doi: https://doi.org/10.1007/s11102-019-01010-5Levin G, Rottenstreich A. Prolactin, prolactin disorders, and dopamine agonists during pregnancy. Hormones. 2019;18(2):137-139. doi: https://doi.org/10.1007/s42000-018-0071-zLevin G, Rottenstreich A. Prolactin, prolactin disorders, and dopamine agonists during pregnancy. Hormones. 2019;18(2):137-139. doi: https://doi.org/10.1007/s42000-018-0071-zBronstein MD. Prolactinomas and pregnancy. Pituitary. 2005;8(1):31-38. doi: https://doi.org/10.1007/s11102-005-5083-4Bronstein MD. Prolactinomas and pregnancy. Pituitary. 2005;8(1):31-38. doi: https://doi.org/10.1007/s11102-005-5083-4Rigg LA, Lein A, Yen SSC. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol. 1977;129(4):454-456. doi: https://doi.org/10.1016/0002-9378(77)90594-4Rigg LA, Lein A, Yen SSC. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol. 1977;129(4):454-456. doi: https://doi.org/10.1016/0002-9378(77)90594-4Gonzalez JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: An in Vivo study using magnetic resonance imaging. Am J Med. 1988;85(2):217-220. doi: https://doi.org/10.1016/S0002-9343(88)80346-2Gonzalez JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: An in Vivo study using magnetic resonance imaging. Am J Med. 1988;85(2):217-220. doi: https://doi.org/10.1016/S0002-9343(88)80346-2Daly AF, Beckers A. Update on the treatment of pituitary adenomas: Familial and genetic considerations. Acta Clin Belg. 2008;63(6):418-424. doi: https://doi.org/10.1179/acb.2008.086Daly AF, Beckers A. Update on the treatment of pituitary adenomas: Familial and genetic considerations. Acta Clin Belg. 2008;63(6):418-424. doi: https://doi.org/10.1179/acb.2008.086Crosignani PG, Mattei AM, Severini V, et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol. 1992;44(3):175-180. doi: https://doi.org/10.1016/0028-2243(92)90094-FCrosignani PG, Mattei AM, Severini V, et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol. 1992;44(3):175-180. doi: https://doi.org/10.1016/0028-2243(92)90094-FMolitch ME. Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am. 2006;35(1):99-116. doi: https://doi.org/10.1016/j.ecl.2005.09.011Molitch ME. Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am. 2006;35(1):99-116. doi: https://doi.org/10.1016/j.ecl.2005.09.011Konopka P, Raymond JP, Merceron RE, Seneze J. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol. 1983;146(8):935-938. doi: https://doi.org/10.1016/0002-9378(83)90968-7Konopka P, Raymond JP, Merceron RE, Seneze J. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol. 1983;146(8):935-938. doi: https://doi.org/10.1016/0002-9378(83)90968-7van Roon E, van Der Vijver JCM, Gerretsen G, et al. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil Steril. 1981;36(2):173-177. doi: https://doi.org/10.1016/S0015-0282(16)45674-8van Roon E, van Der Vijver JCM, Gerretsen G, et al. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil Steril. 1981;36(2):173-177. doi: https://doi.org/10.1016/S0015-0282(16)45674-8Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary. 2001;4(3):179-185. doi: https://doi.org/10.1023/A:1015319007880Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary. 2001;4(3):179-185. doi: https://doi.org/10.1023/A:1015319007880Iglesias P, Díez JJ. Macroprolactinoma: a diagnostic and therapeutic update. QJM. 2013;106(6):495-504. doi: https://doi.org/10.1093/qjmed/hcs240Iglesias P, Díez JJ. Macroprolactinoma: a diagnostic and therapeutic update. QJM. 2013;106(6):495-504. doi: https://doi.org/10.1093/qjmed/hcs240Donoho DA, Laws ER. The role of surgery in the management of prolactinomas. Neurosurg Clin N Am. 2019;30(4):509-514. doi: https://doi.org/10.1016/j.nec.2019.05.010Donoho DA, Laws ER. The role of surgery in the management of prolactinomas. Neurosurg Clin N Am. 2019;30(4):509-514. doi: https://doi.org/10.1016/j.nec.2019.05.010Molitch ME. Endocrinology in pregnancy: Management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-R213. doi: https://doi.org/10.1530/EJE-14-0848Molitch ME. Endocrinology in pregnancy: Management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-R213. doi: https://doi.org/10.1530/EJE-14-0848Huang W, Molitch ME. Pituitary tumors in pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004Huang W, Molitch ME. Pituitary tumors in pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004Domingue ME, Devuyst F, Alexopoulou O, et al. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf ). 2014;80(5):642-648. doi: https://doi.org/10.1111/cen.12370Domingue ME, Devuyst F, Alexopoulou O, et al. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf ). 2014;80(5):642-648. doi: https://doi.org/10.1111/cen.12370Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline Treatment of Risperidone-Induced Hyperprolactinemia. J Clin Psychiatry. 2004;65(2):187-190. doi: https://doi.org/10.4088/JCP.v65n0207Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline Treatment of Risperidone-Induced Hyperprolactinemia. J Clin Psychiatry. 2004;65(2):187-190. doi: https://doi.org/10.4088/JCP.v65n0207Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am. 1992;21(4):877-901. doi: https://doi.org/10.1016/S0889-8529(18)30193-2Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am. 1992;21(4):877-901. doi: https://doi.org/10.1016/S0889-8529(18)30193-2Delcour C, Robin G, Young J, Dewailly D. PCOS and hyperprolactinemia: what do we know in 2019? Clin Med Insights Reprod Heal. 2019;13(4):117955811987192. doi: https://doi.org/10.1177/1179558119871921Delcour C, Robin G, Young J, Dewailly D. PCOS and hyperprolactinemia: what do we know in 2019? Clin Med Insights Reprod Heal. 2019;13(4):117955811987192. doi: https://doi.org/10.1177/1179558119871921Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6(4):245-249. doi: https://doi.org/10.1016/S0272-6386(85)80181-5Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6(4):245-249. doi: https://doi.org/10.1016/S0272-6386(85)80181-5Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab. 1979;48(1):101-107. doi: https://doi.org/10.1210/jcem-48-1-101Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab. 1979;48(1):101-107. doi: https://doi.org/10.1210/jcem-48-1-101Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50(5):846-852. doi: https://doi.org/10.1210/jcem-50-5-846Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50(5):846-852. doi: https://doi.org/10.1210/jcem-50-5-846Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978;64(5):782-787. doi: https://doi.org/10.1016/0002-9343(78)90558-2Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978;64(5):782-787. doi: https://doi.org/10.1016/0002-9343(78)90558-2Далантаева Н.С., Дедов И.И. Генетические и обменные особенности семейных изо-лированных аденом гипофиза // Ожирение и метаболизм. — 2013. — Т. 10 — №2. — С. 3-10. [Dalantaeva NS, Dedov II. Genetic and metabolic characteristics of familial isolated pituitary adenomas. Obesity and metabolism. 2013;10(2):3-10. (In Russ.)]. doi: https://doi.org/10.14341/2071-8713-4817Далантаева Н.С., Дедов И.И. Генетические и обменные особенности семейных изо-лированных аденом гипофиза // Ожирение и метаболизм. — 2013. — Т. 10 — №2. — С. 3-10. [Dalantaeva NS, Dedov II. Genetic and metabolic characteristics of familial isolated pituitary adenomas. Obesity and metabolism. 2013;10(2):3-10. (In Russ.)]. doi: https://doi.org/10.14341/2071-8713-4817Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf ). 2010;72(3):377-382. doi: https://doi.org/10.1111/j.1365-2265.2009.03667.xFernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf ). 2010;72(3):377-382. doi: https://doi.org/10.1111/j.1365-2265.2009.03667.xBenlian P, Giraud S, Lahlou N, et al. Familial acromegaly: a specific clinical entity—Further evidence from the genetic study of a three-generation family. Eur J Endocrinol. 1995;133(4):451-456. doi: https://doi.org/10.1530/eje.0.1330451Benlian P, Giraud S, Lahlou N, et al. Familial acromegaly: a specific clinical entity—Further evidence from the genetic study of a three-generation family. Eur J Endocrinol. 1995;133(4):451-456. doi: https://doi.org/10.1530/eje.0.1330451Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371(25):2363-2374. doi: https://doi.org/10.1056/NEJMoa1408028Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371(25):2363-2374. doi: https://doi.org/10.1056/NEJMoa1408028Xekouki P, Stratakis CA. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer. 2012;19(6):C33-C40. doi: https://doi.org/10.1530/ERC-12-0118Xekouki P, Stratakis CA. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer. 2012;19(6):C33-C40. doi: https://doi.org/10.1530/ERC-12-0118Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64(4):270-283. doi: https://doi.org/10.1097/00005792-198507000-00007Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64(4):270-283. doi: https://doi.org/10.1097/00005792-198507000-00007Georgitsi M, De Menis E, Cannavò S, et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf ). 2008;69(4):621-627. doi: https://doi.org/10.1111/j.1365-2265.2008.03266.xGeorgitsi M, De Menis E, Cannavò S, et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf ). 2008;69(4):621-627. doi: https://doi.org/10.1111/j.1365-2265.2008.03266.xCutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003;28(S1):69-82. doi: https://doi.org/10.1016/S0306-4530(02)00113-0Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003;28(S1):69-82. doi: https://doi.org/10.1016/S0306-4530(02)00113-0Knegtering H, van der Moolen AEGM, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28:109-123. doi: https://doi.org/10.1016/S0306-4530(02)00130-0Knegtering H, van der Moolen AEGM, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28:109-123. doi: https://doi.org/10.1016/S0306-4530(02)00130-0Smith S, Wheeler MJ, Murray R, O’Keane V. The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis. J Clin Psychopharmacol. 2002;22(2):109-114. doi: https://doi.org/10.1097/00004714-200204000-00002Smith S, Wheeler MJ, Murray R, O’Keane V. The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis. J Clin Psychopharmacol. 2002;22(2):109-114. doi: https://doi.org/10.1097/00004714-200204000-00002Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neurolepticinduced hyperprolactinemia. Fertil Steril. 1988;50(6):876-881. doi: https://doi.org/10.1016/S0015-0282(16)60365-5Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neurolepticinduced hyperprolactinemia. Fertil Steril. 1988;50(6):876-881. doi: https://doi.org/10.1016/S0015-0282(16)60365-5Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004;65(12):1607-1618. doi: https://doi.org/10.4088/JCP.v65n1205Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004;65(12):1607-1618. doi: https://doi.org/10.4088/JCP.v65n1205Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest. 2000;23(11):765-770. doi: https://doi.org/10.1007/BF03345068Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest. 2000;23(11):765-770. doi: https://doi.org/10.1007/BF03345068Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983;309(5):280-283. doi: https://doi.org/10.1056/NEJM198308043090505Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983;309(5):280-283. doi: https://doi.org/10.1056/NEJM198308043090505Glezer A, Bronstein MD. Prolactinomas, cabergoline, and pregnancy. Endocrine. 2014;47(1):64-69. doi: https://doi.org/10.1007/s12020-014-0334-7Glezer A, Bronstein MD. Prolactinomas, cabergoline, and pregnancy. Endocrine. 2014;47(1):64-69. doi: https://doi.org/10.1007/s12020-014-0334-7Sant’ Anna BG, Musolino NRC, Gadelha MR, et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary. 2020;23(2):120-128. doi: https://doi.org/10.1007/s11102-019-01008-zSant’ Anna BG, Musolino NRC, Gadelha MR, et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary. 2020;23(2):120-128. doi: https://doi.org/10.1007/s11102-019-01008-z

The authors declare that there are no conflicts of interest present.